X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (51182) 51182
Book Review (5656) 5656
Publication (3231) 3231
Newsletter (1792) 1792
Book Chapter (138) 138
Newspaper Article (74) 74
Conference Proceeding (63) 63
Dissertation (43) 43
Magazine Article (38) 38
Book / eBook (16) 16
Data Set (5) 5
Reference (3) 3
Government Document (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (44853) 44853
humans (42598) 42598
female (24965) 24965
male (23159) 23159
oncology (21364) 21364
middle aged (20183) 20183
adenocarcinoma - drug therapy (19880) 19880
adenocarcinoma (18359) 18359
aged (18197) 18197
cancer (16326) 16326
adult (12899) 12899
adenocarcinoma - pathology (12149) 12149
chemotherapy (10600) 10600
animals (9261) 9261
antineoplastic combined chemotherapy protocols - therapeutic use (8154) 8154
prognosis (7383) 7383
carcinoma (6640) 6640
treatment outcome (6535) 6535
mice (6338) 6338
aged, 80 and over (6171) 6171
cell line, tumor (6065) 6065
lung neoplasms - drug therapy (6045) 6045
research (6017) 6017
care and treatment (5743) 5743
neoplasm staging (5606) 5606
tumors (5600) 5600
metastasis (5489) 5489
surgery (5442) 5442
pancreatic cancer (5076) 5076
adenocarcinoma - surgery (4895) 4895
expression (4885) 4885
survival (4795) 4795
antineoplastic agents - therapeutic use (4718) 4718
lung neoplasms - pathology (4647) 4647
apoptosis (4616) 4616
lung cancer (4613) 4613
adenocarcinoma - metabolism (4593) 4593
adenocarcinoma - genetics (4536) 4536
analysis (4466) 4466
adenocarcinoma - secondary (4376) 4376
therapy (4152) 4152
abridged index medicus (4104) 4104
combined modality therapy (4052) 4052
survival rate (3958) 3958
adenocarcinoma - mortality (3875) 3875
health aspects (3814) 3814
retrospective studies (3766) 3766
fluorouracil - administration & dosage (3540) 3540
medicine & public health (3474) 3474
mutation (3431) 3431
pancreatic neoplasms - drug therapy (3409) 3409
adenocarcinoma - therapy (3324) 3324
follow-up studies (3300) 3300
lung neoplasms - genetics (3224) 3224
genetic aspects (3217) 3217
stomach neoplasms - drug therapy (3170) 3170
immunohistochemistry (3089) 3089
gastroenterology & hepatology (2975) 2975
cancer therapies (2916) 2916
pancreatic neoplasms - pathology (2893) 2893
gene expression (2888) 2888
cisplatin - administration & dosage (2875) 2875
drug therapy (2864) 2864
adenocarcinoma - radiotherapy (2859) 2859
survival analysis (2796) 2796
disease-free survival (2750) 2750
antineoplastic agents - pharmacology (2727) 2727
cisplatin (2680) 2680
deoxycytidine - analogs & derivatives (2675) 2675
stomach neoplasms - pathology (2670) 2670
chemotherapy, adjuvant (2663) 2663
pharmacology & pharmacy (2635) 2635
gemcitabine (2627) 2627
radiotherapy (2612) 2612
proteins (2577) 2577
colorectal cancer (2533) 2533
development and progression (2505) 2505
carcinoma, squamous cell - drug therapy (2486) 2486
apoptosis - drug effects (2450) 2450
prostatic neoplasms - drug therapy (2405) 2405
pathology (2396) 2396
time factors (2384) 2384
carcinoma, non-small-cell lung - drug therapy (2380) 2380
antineoplastic combined chemotherapy protocols - adverse effects (2378) 2378
patients (2374) 2374
risk factors (2337) 2337
cell biology (2332) 2332
tumor cells, cultured (2327) 2327
mice, nude (2296) 2296
drug administration schedule (2285) 2285
article (2274) 2274
neoplasm metastasis (2257) 2257
breast-cancer (2224) 2224
diagnosis (2168) 2168
medical prognosis (2157) 2157
medicine (2134) 2134
trial (2121) 2121
cells (2082) 2082
oncology, experimental (2047) 2047
growth (2043) 2043
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (49039) 49039
Japanese (1820) 1820
French (645) 645
German (526) 526
Chinese (356) 356
Spanish (239) 239
Russian (231) 231
Italian (155) 155
Polish (41) 41
Hungarian (32) 32
Danish (19) 19
Korean (16) 16
Czech (14) 14
Dutch (11) 11
Portuguese (11) 11
Romanian (11) 11
Swedish (10) 10
Ukrainian (9) 9
Bulgarian (8) 8
Turkish (6) 6
Croatian (5) 5
Lithuanian (5) 5
Norwegian (5) 5
Hebrew (3) 3
Finnish (2) 2
Serbian (2) 2
Slovak (2) 2
Afrikaans (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 368 - 372
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer(1,2). Here we show that targeted therapy with... 
CNS CELL-TYPES | MELANOMA | METASTASIS | MICROENVIRONMENT | TRANSLATIONAL PROFILING APPROACH | MULTIDISCIPLINARY SCIENCES | RAF INHIBITOR RESISTANCE | ACQUIRED-RESISTANCE | KINASE INHIBITORS | DRUG-RESISTANCE | CANCER CHEMORESISTANCE | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Clone Cells - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Proto-Oncogene Proteins c-fos - deficiency | Adenocarcinoma - metabolism | Neoplasm Metastasis - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Tumor Microenvironment - drug effects | Cell Survival - drug effects | Melanoma - pathology | Down-Regulation - drug effects | Enzyme Activation - drug effects | Adenocarcinoma - drug therapy | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Lung Neoplasms - secretion | Melanoma - secretion | Animals | Clone Cells - pathology | Metabolome - drug effects | Signal Transduction - drug effects | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adenocarcinoma - secretion | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Pharmaceutical research | Care and treatment | Oncology, Experimental | Dosage and administration | Research | Drug therapy | Drug resistance | Antineoplastic agents | Tumors | Cancer | Melanoma | Mutation | Metastasis | Kinases | Cancer therapies | Index Medicus
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 10/2018, Volume 14, Issue 7, pp. 2295 - 2305
Journal Article
Computer Methods and Programs in Biomedicine, ISSN 0169-2607, 2014, Volume 115, Issue 3, pp. 162 - 170
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 976 - 983
Journal Article
Cell Death and Disease, ISSN 2041-4889, 10/2013, Volume 4, Issue 10, pp. e828 - e828
Accumulating evidence indicates that cancer-initiating cells (CICs) are responsible for cancer initiation, relapse, and metastasis. Colorectal carcinoma (CRC)... 
Rectal adenocarcinoma | Cancer-initiating cells (CICs) | CD44 | Chemoresistance | CD54 | 1ST-LINE TREATMENT | STEM-CELLS | TUMOR PROGRESSION | ALDEHYDE DEHYDROGENASE | IDENTIFICATION | METASTATIC COLORECTAL-CANCER | CELL BIOLOGY | COLON-CANCER | chemoresistance | rectal adenocarcinoma | cancer-initiating cells (CICs) | GROWTH | EXPANSION | EXPRESSION | Adenocarcinoma - pathology | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Humans | Spheroids, Cellular - pathology | Epithelial-Mesenchymal Transition - drug effects | Organoplatinum Compounds - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Fluorouracil - therapeutic use | Neoplastic Stem Cells - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Hyaluronan Receptors - metabolism | Neoplastic Stem Cells - pathology | Leucovorin - therapeutic use | Rectal Neoplasms - pathology | Spheroids, Cellular - drug effects | Cetuximab | Culture Media, Serum-Free - pharmacology | Rectal Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Adenocarcinoma - drug therapy | Carcinogenesis - drug effects | Carcinogenesis - pathology | Xenograft Model Antitumor Assays | Intercellular Adhesion Molecule-1 - metabolism | Phenotype | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Differentiation - drug effects | Cell Proliferation - drug effects | Fluorouracil - pharmacology | Mice | Leucovorin - pharmacology | Mesoderm - pathology | Organoplatinum Compounds - therapeutic use | Drug Resistance, Neoplasm - drug effects | Index Medicus | Original | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4015 - 4022
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1224 - 1235
Summary Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | ONCOLOGY | BEVACIZUMAB | CLINICAL-TRIALS | GROWTH | 2ND-LINE CHEMOTHERAPY | OPEN-LABEL | 1ST-LINE THERAPY | COMBINATION | CANCER | III TRIAL | Confidence Intervals | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Esophageal Neoplasms - mortality | Adult | Female | Remission Induction - methods | Paclitaxel - administration & dosage | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Paclitaxel - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Hospitals | Clinical trials | Monoclonal antibodies | Product development | Antineoplastic agents | Vascular endothelial growth factor | Esophageal cancer | Index Medicus
Journal Article
Immunity, ISSN 1074-7613, 02/2016, Volume 44, Issue 2, pp. 343 - 354
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Index Medicus | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 747 - 756
Journal Article